Results 221 to 230 of about 1,694,367 (292)

Dual Role of Tamoxifen in Enhancing STING and CEACAM1 Expression to Prime a Favorable Tumor Microenvironment for Anti‐TIM3 Immunotherapy

Advanced Science, EarlyView.
Anti‐PD‐1/PD‐L1 blockade has revolutionized cancer immunotherapy, but is ineffective against endocrine‐treated (i.e., Tamoxifen), relapsed ER+ breast cancer (BC) patients. This study provides insight into the sub‐optimal response of ER+BCs to anti‐PD‐1/PD‐L1 blockade – highlighting the induction of STING and the CEACAM1/TIM3 axis after chronic ...
Marvin Angelo E Aberin, Saurabh Singh, Soumya Chatterjee, Guang‐Zhi Sui, Yi‐Fu Wang, Ya‐Ting Lu, Yu‐Ling Lee, Kun‐Yuan Lin, Joy Khag, Ta‐Yu Liu, Shao‐Han Chang, Wai‐Mui Cheung, Hsiao‐Chin Hong, Ren‐Jun Hsu, Chen‐Yang Shen, Chia‐Wei Li, Weng‐Lang Yang, Yao‐Ming Chang, Shih‐Yu Chen, Chandan Guha, Shu‐Ping Wang   +20 more
wiley   +1 more source

Breaking barriers: nanosystems to overcome solubility and permeability challenges of second-generation tyrosine kinase inhibitors. [PDF]

Beilstein J Nanotechnol
Shree B, Sharma A, Kumar M, Chawla R, Mishra B.   +4 more
europepmc   +1 more source

Deep Contrastive Learning for High‐Throughput Prediction of Drug Resistance Mutations from Sequences

Advanced Science, EarlyView.
This study presents DeepMutDTA, a deep learning framework aimed at predicting mutation‐induced changes in protein‐drug interactions and prioritizing variants potentially linked to drug resistance. Trained on large‐scale data, it incorporates SimSiam‐MuTF, a label‐aware contrastive fine‐tuning strategy that encourages separation between WT and MT ...
Xiaowen Hu, Pan Zhang, Shangqian Wu, Hao Sun, Minwei Li, Sophia Tsoka, Zizhang Sheng, Lei Deng   +7 more
wiley   +1 more source

Novel Indazole Compounds as PKMYT1 Kinase Inhibitors for Treating Cancer. [PDF]

ACS Med Chem Lett
Sabnis RW.
europepmc   +1 more source

Rab1A Promotes Hepatic Steatosis by Suppressing Mitophagy via the Raf‐1/ERK1/2/PINK1 Signaling Axis

Advanced Science, EarlyView.
Why does fat accumulate in the liver? Our study reveals Rab1A as the molecular switch that silences the cell's mitochondrial cleanup crew. Turning Rab1A off reactivates mitophagy, clears excess fat, and reverses fatty liver disease in mice—offering a promising new therapeutic target for MASLD, a growing global health challenge.
Li Zhang, Jianhua Li, Huilu Zhang, Qi Qin, Yichen Huang, Xiaofan Tian, Chao Sun, Binbin Li, Zhengxin Wang, Xin Zhang   +9 more
wiley   +1 more source

Treatment response and survival outcomes with BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: a retrospective study. [PDF]

Front Med (Lausanne)
Liu Y, Zhang L, Zeng L.
europepmc   +1 more source

Editorial: The molecular mechanisms and therapeutic implications of protein kinase inhibitors in cancer therapy. [PDF]

Front Med (Lausanne)
Sun YH, Guo FY, Lee MH, Dhanasekaran D, Jin CH.   +4 more
europepmc   +1 more source

Real-World Experience with Janus Kinase Inhibitors in Severe Refractory Hidradenitis Suppurativa: A Retrospective Case Series. [PDF]

Clin Cosmet Investig Dermatol
Dai Y, Han Y, Zhang S, Chen H, Yi Q, Jiang X.   +5 more
europepmc   +1 more source

Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy. [PDF]

Res Pract Thromb Haemost
Kartika T, Buitrago L, Li J, Cunningham-Rundles C, Coller BS.   +4 more
europepmc   +1 more source